Judy Ashworth

590 total citations
15 papers, 430 citations indexed

About

Judy Ashworth is a scholar working on Public Health, Environmental and Occupational Health, Pharmacology and Toxicology. According to data from OpenAlex, Judy Ashworth has authored 15 papers receiving a total of 430 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Public Health, Environmental and Occupational Health, 5 papers in Pharmacology and 4 papers in Toxicology. Recurrent topics in Judy Ashworth's work include Opioid Use Disorder Treatment (9 papers), Pain Mechanisms and Treatments (4 papers) and Forensic Toxicology and Drug Analysis (4 papers). Judy Ashworth is often cited by papers focused on Opioid Use Disorder Treatment (9 papers), Pain Mechanisms and Treatments (4 papers) and Forensic Toxicology and Drug Analysis (4 papers). Judy Ashworth collaborates with scholars based in United States, Germany and United Kingdom. Judy Ashworth's co-authors include Sandra D. Comer, Richard W. Foltin, Mila Etropolski, Sharon Walsh, Bernd Lange, Chris E. Johanson, Brigitte Kuperwasser, James P. Zacny, Thomas Häufel and Akiko Okamoto and has published in prestigious journals such as Scientific Reports, Psychopharmacology and Addiction.

In The Last Decade

Judy Ashworth

15 papers receiving 408 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Judy Ashworth United States	11	159	137	127	120	111	15	430
Karen Rubinstein United States	4	271 1.7×	106 0.8×	118 0.9×	114 0.9×	86 0.8×	5	536
Anne Roussin France	16	146 0.9×	58 0.4×	99 0.8×	102 0.8×	219 2.0×	42	696
Ryan K. Lanier United States	14	122 0.8×	140 1.0×	93 0.7×	92 0.8×	81 0.7×	29	488
Eveline van Dorp Netherlands	10	196 1.2×	75 0.5×	57 0.4×	129 1.1×	73 0.7×	14	440
João P. De Aquino United States	10	132 0.8×	34 0.2×	141 1.1×	77 0.6×	58 0.5×	43	341
Anthony Campbell United Kingdom	13	134 0.8×	90 0.7×	79 0.6×	55 0.5×	82 0.7×	53	695
Sandra Gutiérrez United States	12	180 1.1×	90 0.7×	36 0.3×	106 0.9×	92 0.8×	15	406
Peter A. DeMaria United States	10	115 0.7×	80 0.6×	51 0.4×	90 0.8×	164 1.5×	20	401
Kok Eng Khor Australia	8	104 0.7×	38 0.3×	195 1.5×	87 0.7×	35 0.3×	15	386
Hans Bijl Netherlands	7	155 1.0×	205 1.5×	73 0.6×	228 1.9×	81 0.7×	7	538

Countries citing papers authored by Judy Ashworth

Since Specialization

Citations

This map shows the geographic impact of Judy Ashworth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judy Ashworth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judy Ashworth more than expected).

Fields of papers citing papers by Judy Ashworth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judy Ashworth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judy Ashworth. The network helps show where Judy Ashworth may publish in the future.

Co-authorship network of co-authors of Judy Ashworth

This figure shows the co-authorship network connecting the top 25 collaborators of Judy Ashworth. A scholar is included among the top collaborators of Judy Ashworth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judy Ashworth. Judy Ashworth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Moline, Margaret, Shoji Asakura, Ishani Landry, et al.. (2023). The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act. Psychopharmacology. 240(4). 699–711. 15 indexed citations

Henningfield, Jack E., Judy Ashworth, David J. Heal, & Sharon L. Smith. (2023). Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective. Journal of Psychopharmacology. 37(1). 33–44. 9 indexed citations

Henningfield, Jack E., David V. Gauvin, Francesco Bifari, et al.. (2022). REL-1017 (esmethadone; d-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats. Scientific Reports. 12(1). 11389–11389. 10 indexed citations

Henningfield, Jack E., et al.. (2019). The nexus of opioids, pain, and addiction: Challenges and solutions. Preventive Medicine. 128. 105852–105852. 10 indexed citations

Comer, Sandra D., Judy Ashworth, Maria A. Sullivan, et al.. (2018). Relationship between rate of infusion and reinforcing strength of oxycodone in humans. Journal of Opioid Management. 5(4). 203–212. 15 indexed citations

Deng, Xiaoli, et al.. (2016). Utility of Antinuclear Antibody Screening by Various Methods in a Clinical Laboratory Patient Cohort. The Journal of Applied Laboratory Medicine. 1(1). 36–46. 10 indexed citations

Vosburg, Suzanne K., et al.. (2015). Prescription Opioid Abuse, Prescription Opioid Addiction, and Heroin Abuse Among Adolescents in a Recovery High School: A Pilot Study. Journal of Child & Adolescent Substance Abuse. 25(2). 105–112. 13 indexed citations

Vosburg, Suzanne K., Jermaine D. Jones, Jeanne M. Manubay, et al.. (2013). A comparison among tapentadol tamper‐resistant formulations (TRF) and OxyContin^® (non‐TRF) in prescription opioid abusers. Addiction. 108(6). 1095–1106. 31 indexed citations

Vosburg, Suzanne K., Jermaine D. Jones, Jeanne M. Manubay, et al.. (2012). Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug and Alcohol Dependence. 126(1-2). 206–215. 39 indexed citations

10.

Sindrup, Søren H., R. Lehmann, T. Meier, et al.. (2011). Randomized controlled trial of the combined monoaminergic and opioid investigational compoundGRT9906in painful polyneuropathy. European Journal of Pain. 16(6). 849–859. 15 indexed citations

11.

Lange, Bernd, Brigitte Kuperwasser, Akiko Okamoto, et al.. (2010). Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Advances in Therapy. 27(6). 381–399. 136 indexed citations

12.

Ashworth, Judy, Brigitte Kuperwasser, Mila Etropolski, et al.. (2010). 334 ASSESSMENT OF OPIOIDWITHDRAWAL IN PATIENTS TREATED WITH TAPENTADOL PROLONGED RELEASE DURING AN OPEN-LABEL EXTENSION STUDY. Osteoarthritis and Cartilage. 18. S148–S148. 5 indexed citations

13.

Biondi, David M., Jim Xiang, G. Vorsanger, et al.. (2010). Tapentadol extended release (ER) versus oxycodone controlled release (CR) for management of chronic low back or osteoarthritis pain: influence of prior opioid experience on study discontinuations due to constipation, nausea, or vomiting. Journal of Pain. 11(4). S42–S42. 2 indexed citations

14.

Comer, Sandra D., Judy Ashworth, Richard W. Foltin, et al.. (2008). The role of human drug self-administration procedures in the development of medications. Drug and Alcohol Dependence. 96(1-2). 1–15. 119 indexed citations

15.

Ashworth, Judy. (1969). Spinal injuries and fractures.. BMJ. 4(5680). 414–415. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact